An Overview of Systematic Reviews of Shenmai Injection for Healthcare

Abstract EN

Shenmai injection (SMI) is widely applied in clinical practice as an organ protector.

This overview is to evaluate the current evidence from systematic reviews (SRs) of SMI for healthcare.

The literature searches were carried out in 6 databases without language restrictions until December 2012.

The quality of the primary studies from the respective SRs was evaluated by using Jadad score.

The overview quality assessment questionnaire (OQAQ) was used to evaluate the methodological quality of all included SRs.

Twenty eligible SRs were identified.

They reported a wide range of conditions, including SMI for cardio/cerebrovascular diseases, viral myocarditis, tumor chemotherapy, and adverse drug reactions.

Most of the primary studies were of good quality only in 1 SR of non-small-cell lung cancer.

According to the OQAQ scores, the quality of included SRs was variable and six reviews were of high quality with a score of 5 points.

Two SRs showed that SMI had low adverse drug reaction occurrence.

In conclusion, there is mixed evidence to support efficacy of SMI for an adjunct therapy to tumor chemotherapy and premature evidence for the use of SMI for cardio/cerebrovascular disorders and viral myocarditis.

SMI seems generally safe for clinical application.

Further large sample-size and well-designed RCTs are needed.